Phone: 888-558-5227

651-644-8424

888-558-7329 Fax:

Email: getinfo@lktlabs.com Web: lktlabs.com

Product Information

Product ID R3584

CAS No. 366789-02-8

Chemical Name

Synonym

Formula C₁₉H₁₈ClN₃O₅S

Formula Wt. 435.88

Melting Point

Purity ≥98% Solubility MeOH

Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
R3584	1 mg	\$107.20
R3584	5 mg	\$370.90
R3584	25 mg	\$1318.40

Store Temp Ambient Ship Temp Ambient

Description Rivaroxaban is an orally bioavailable oxazolidone derivative that acts as an antithrombotic/anticoagulant, reversibly inhibiting factor Xa. Rivaroxaban directly binds to the S1 and S4 pockets of factor Xa and inhibits both free and clot-bound forms. In vitro models indicate that rivaroxaban may also exert inhibitory effects during the early stages of bone formation, as it inhibits hormone-stimulated modulation of ER and 1-OHase expression as well as DNA synthesis, creatine kinase activity, and alkaline phosphatase activity. TEST!!!!!!

References Kreutz R. Pharmacokinetics and Pharmacodynamics of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor. Curr Clin Pharmacol. 2013 Nov 11. [Epub ahead of print]. PMID: 24218999.

> Somjen D, Katzburg S, Gigi R, et al. Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonalinduced physiological modulations in human female osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol. 2013 May;135:67 -70. PMID: 23333933

Gigi R, Salai M, Dolkart O, et al. The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2. Connect Tissue Res. 2012;53(6):446-50. PMID: 22800431.

Samama MM. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. Thromb Res. 2011 Jun;127(6):497-504. PMID: 20888031.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.